Analysis of incidence of SARS-CoV-2 infections
SARS-CoV-2 infection
ASYMPTOMATIC SARS-COV-2 INFECTION, SARS-COV-2 INFECTION
The primary analysis population to assess the incidence of symptomatic SARS-CoV-2 infection (COVID-19), asymptomatic SARS-CoV-2 infection and SARS-CoV-2 infection was the primary set for efficacy. The number and percentage of participants with asymptomatic or symptomatic SARS-CoV-2 infection and COVID-19-events post booster are summarized starting 14 days post booster regardless of prebooster SARS-CoV-2 infection status.